NCT00431613 - Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Docetaxel

Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles

DRUG

Gemcitabine

Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles

DRUG

Carboplatin

Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles

RADIATION

Chemoradiotherapy

"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"

DRUG

Docetaxel

Docetaxel 75mg/m2 IV on day 1 for 3 cycles

Trial Locations (10)

71110

University Hospital of Crete, Heraklion

Unknown

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

401 Military Hospital, Medical Oncology Unit, Athens

Air Forces Military Hospital, Dep of Medical Oncology, Athens

IASO General Hospital of Athens, 1st Dep of Medical Oncology, Athens

Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens

Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens

Sotiria General Hospital, 1st, 3rd, 6th, 7th, 8th Dep of Pulmonary Diseases, Athens

Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus

Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki